Specific regulation of point-mutated K-ras-immortalized cell proliferation by a photodynamic antisense strategy

Oligonucleotides

Volumn 20, Issue 1, 2010, Pages 37-43

  Higuchi, Maiko ^a   Yamayoshi, Asako ^a   Kato, Kiyoko ^b   Kobori, Akio ^a   Wake, Norio ^c   Murakami, Akira ^a  

^a KYOTO INSTITUTE OF TECHNOLOGY   (Japan)

^b Department of Molecular Genetics

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2' O PSORALENYLMETHOXYETHYL ADENOSINE; ANTISENSE OLIGONUCLEOTIDE; K RAS PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; CROSS LINKING; EMBRYO; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENE TARGETING; MOUSE; NONHUMAN; PHOTODYNAMICS; POINT MUTATION; PRIORITY JOURNAL; ULTRAVIOLET A RADIATION; WILD TYPE;

ANIMALS; BASE SEQUENCE; CELL LINE, TRANSFORMED; CELL PROLIFERATION; DNA PRIMERS; GENES, RAS; MICE; NIH 3T3 CELLS; PHOTOCHEMOTHERAPY; POINT MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77649095694     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2008.0173     Document Type: Article

References (41)

1. ADJEI, A.A. (2001). Blocking oncogenic ras signaling for cancer therapy. J. Natl. Cancer Inst. 93, 1062-1074.
2. AGRAWAL, S., TEMSAMAMI, J., GALBARAITH, W., and TANG, J. (1995). Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28, 7-16.
3. AGRAWAL, S., TEMSAMAMI, J., and TANG, J.Y. (1991). Pharmacokinetics, biodistribution, and stability of oligonucle-otides phosphorothioates in mice. Proc. Natl. Acad. Sci. USA. 88, 7597-7599.
4. ALMOGUERA, C., SHIBATA, D., FORRESTER, K., MARTIN, J., ARNHEIM, N., and PERUCHO, M. (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 53, 549-554.
5. ANDERSON, K.P., FOX, M.C., BROWN-DRIVER, V., MARTIN, M.J., and AZAD, R.F. (1996). Inhibition of human cytomegalo-virus immediate-early gene expression by an antisense oligo-nucleotides complementary to immediate-early RNA. Agents. Chemother. 40, 2004-2011.
6. AZAD, R.F., DRIVER, V.B., TANAKA, K., CROOKE, R.M., and ANDERSON, K.P. (1993). Antiviral activity of a phosphorothio-ate oligonucleotides complementary to RNA of the Human cyto-megalovirus major immediate-early region. Antimicrob. Agents. Chemother. 37, 1945-1954.
7. BARBACID, M. (1987). ras gene. Annu. Rev. Biochem. 56, 779-827.
8. BIANCO, R., MELISI, D., CIARDIELLO, F., and TORTORA, G. (2006). Key cancer cell signal transduction pathways as therapeutic targets. Eur. J. Cancer 42, 290-294.
9. BOS, J.L. (1989). ras oncogenes in human cancer: a review. Cancer Res. 49, 4682-4689.
10. BRUMMELKAMP, T.R., BERNARDS, R., and AGAMI, R. (2002). Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243-247.
11. CAPELLA, G., CRONAUER-MITRA, S., PEINADO, M.A., and PERUCHO, M. (1991). Frequency and spectrum of mutations at codon 12 and 13 of the c-K-ras gene in human tumors. Environ. Health. Persp. 93, 125-131.
12. CIMINO, G.D., GAMPER, H.B., ISAACS, S., and HEARST, J. (1985). Psoralens as photoactive probes of nucleic acid structure and function: organic chemistry, photochemistry, and biochemistry. Ann. Rev. Biochem. 54, 1151-1193.
13. DASH, P., LOTAN, I., KNAPP, I., KANDEL, E.R., and GOELET, P. (1987). Selective elimination of mRNAs in vivo: complementary oligonucleotides promote RNA degradation by an RNase H-like activity. Proc. Natl. Acad. Sci. USA. 84, 7896-7900.
14. DEAN, N.M., and BANNETT, C.F. (2003). Antisense oligonucle-otides-based therapeutics for cancer. Oncogene. 22, 9087-9096.
15. 1 cell cycle progression. J. Biol. Chem. 274, 22033-22040.
16. GLEAVE, M.E., and MONIA, B.P. (2005). Antisense therapy for cancer. Nat. Rev. Cancer. 5, 468-479.
17. HAEUPTLE, M.T., FRANK, R., and DOBBERSTEIN, B. (1986). Translation arrest by oligonucleotides complementary to mRNA coding sequences yields polypeptides of predetermined length. Nucleic Acids Res. 14, 14 2 7-14 4 8.
18. HIGUCHI, M., SAKAMOTO, T., KOBORI, A., and MURAKAMI, A. (2006). Properties of novel antisense oligonucleotides containing 2′-O-modif ed adenosine with a photo-reactive group. Nucleic Acids Symp. Ser. 50, 301-302.
19. HIGUCHI, M., YAMAYOSHI, A., KOBORI, A., and MURAKAMI, A. (2007a). Selective regulation of mutant K-ras mRNA expression by photo-cross-linking antisense oligonucleotides. Nucleic Acids Symp. Ser. 51, 443-444.
20. HIGUCHI, M., YAMAYOSHI, A., YAMAGUCHI, T., IWASE, R., YAMAOKA, T., and MURAKAMI, A. (2007b). Selective photo-cross-linking of 2′-O-psoralen- conjugated oligonucleotides with RNAs having point mutations. Nucleosides Nucleotides Nucleic Acids 26, 277-290.
21. HOLLSTEIN, M., SIDRANSKY, D., VOGELSTEIN, B., and HARRIS, C.C. (1991). p53 mutations in human cancers. Science 253, 49-53.
22. JACKSON, A.L., BARTZ, S.R., SCHELTER, J., KOBAYASHI, S.V., BURCHARD, J., MAO, M., LI, B., CAVET, G., and LINSLEY, P.S. (2003). Expression prof ling reveals off target gene regulation by RNAi. Nat. Biol. 21, 635-637.
23. 12Va l]K-ras mediated NIH3T3 cell transformation. Oncogene 15, 3037-3046.
24. KEAN, J.M., MURAKAMI, A., BLAKE, K.R., CUSHMAN, C.D., and MILLER, P.S. (1988). Photochemical cross-linking of psoralen-derivatized oligonucleoside methylphosphonates to Rabbit glo-bin messenger RNA. Biochemistry 27, 9113-9121.
25. KURRECK, J. (2003). Antisense technologies. Eur. J. Biochem. 270, 1628-164 4.
26. LEE, B.L., MURAKAMI, A., BLAKE, K.R., LIN, S.B., and MILLER, P.S. (1988). Interaction of psoralen-derivatized oligonucleoside methylphosphonates with single-stranded DNA. Biochemistry 27, 3197-3203.
27. MANOHARAN, M. (2002). Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action. Antisense Nucleic Acid Drug Dev. 12, 103-128.
28. MURAKAMI, A., YAMAYOSHI, A., IWASE, R., NISHIDA, J., YAMAOKA, T., and WAKE, N. (2001). Photodynamic antisense regulation of human cervical carcinoma cell growth using psoralen-conjugated oligo(nucleoside phosphorothioate). Eur. J. Pharma. Sci. 13, 25-34.
29. NINOMIYA, Y., KATO, K., TAKAHASHI, A., UEOKA, Y., KIMIKIHARA, T., ARIMA, T., MATSUDA, T., KATO, H., NISHIDA, J., and WAKE, N. (2004). K-ras and H-ras activation promote distinct consequences on endometrial cell survival. Cancer Res. 64, 2759-2765.
30. OH, D.H., KING, B.A., BOXER, S.G., and HANAWALT, P.C. (2001). Spatially localized generation of nucleotide sequence-specif c DNA damage. Proc. Natl. Acad. Sci. USA. 98, 11271-11276.
31. OH, D.H., STANLEY, R.J., LIN, M., HOEFFLER, W.K., BOXER, S.G., BERNS, M.W., and BAUER, E.A. (1997). Two-photon excitation of 4′-hydroxymethyl-4, 5′-8-trimethylpsoralen. Photochem. Photobiol. 65, 91-95.
32. SAISON-BEHMOARAS, T., TOCQUE, B., REY, I., CHASSIGNOL, M., THOUONG, N.T., and HELENE, C. (1991). Short modif ed antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J. 10, 1111-1118.
33. SCACHERI, P.C., ROZENBLATT-ROSEN, O., CAPLEN, N.J., WOLFSBERG, T.G., UMAYAM, L., LEE, J.C., HUGHES, C.M., SHANMUGAM, K.S., BHATTACHARJEE, A., MEYERSON, M., and COLLINS, F.S. (2004). Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc. Natl. Acad. Sci. USA. 101, 1892-1897.
34. SMIT, V.T.H.B.M., BOOT, A.J.M., SMITS, A.M.M., FLEUREN, G.J., CORNELISSE, C.J., and BOS, J.L. (1988). KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 16, 7773-7782.
35. STEIN, C.A., and CHENG, Y.C. (1993). Antisense oligonucleotides as therapeutic agents is the bullet really magical?. Science 261, 1004-1012.
36. TAKESHITA, F., and OCHIYA, T. (2006). Therapeutic potential of RNA interference against cancer. Cancer Sci. 97, 689-696.
37. TAKUWA, N., and TAKUWA, Y. (2001). Regulation of cell cycle molecules by the ras effecter system. Mol. Cell. Endocrinol. 177, 25-33.
38. TRAHEY, M., and MCCORMICK, F. (1987). A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect onco-genic mutants. Science 238, 542-545.
39. YAMAMOTO, F., and PERUCHO, M. (1984). Activation of a human c-K-ras oncogene. Nucleic Acids Res. 12, 8873-8885.
40. YAMAYOSHI, A., KATO, K., SUGA, S., ICHINOE, A., ARIMA, T., MATSUDA, T., KATO, H., MURAKAMI, A., and WAKE, N. (2007). Specif c apoptosis induction in human papillomavirus-positive cervical carcinoma cells by photodynamic antisense regulation. Oligonucleotide 17, 66-79.
41. ZHANG, Z., JIANG, G., YANG, F., and WANG, J. (2006). Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells. Cancer Biol. Ther. 5, 14 81-14 8 6. (Pubitemid 46256617)